

February 11, 2021

Eezcare Medical Corp % John Gillespy President FDA 510k Consultants, LLC 1100 Del Lago Cir, Ste 104 Palm Beach Gardens, Florida 33410

Re: K193662

Trade/Device Name: Ezlymph, Ezlymph M Regulation Number: 21 CFR 870.5800

Regulation Name: Compressible Limb Sleeve

Regulatory Class: Class II Product Code: JOW Dated: January 7, 2021 Received: January 11, 2021

### Dear John Gillespy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Fernando Aguel
Assistant Director
DHT2B: Division of Circulatory Support,
Structural and Vascular Devices
OHT2: Office of Cardiovascular Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

## DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

### **Indications for Use**

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known)	
K193662	
Device Name EzLymph and EzLymph M	
Indications for Use (Describe) EzLymph and EzLymph M are intended to treat lymphedema.	
Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

### Section 5 – 510(k) Summary

1. 510(k) Submitter: Eezcare Medical Corp

No. 3-1, Minquan St., New Taipei City 236 Taipei, Tu-Cheng District, Taiwan 23679

Phone: 757-224-0177

Email: michelle.mitchell@eezcare.com.tw

2. Company Contact: Michelle C. Mitchell

3. Date of Submission: December 29, 2019

4. 510(k) Preparer: John F. Gillespy, MBA

FDA 510k Consulting, LLC Palm Beach Gardens, FL 33410

Phone: 386-243-4332

Email: john@fda510kconsultants.com

5. Device Classification: Trade name: EzLymph, EzLymph M

Common name: Lymphedema Pump System Device: Sleeve, Limb, Compressible

Class: II Product Code: JOW

6. Predicate: Applicant: ArjoHuntleigh AB (Sweden)

Device: Hydroven 3 Pump, Hydroven FPR

Pump, Hydroven Garments

510(k) Number: K910188

Reference: Applicant: Tactile Medical

Device: Flexitouch System

510(k) Number: K170216

7. <u>Device Description</u>... **EzLymph** and **EzLymph M** is a pump system intended to apply intermittent pneumatic compression (IPC) to arms and legs to relieve the discomfort of lymphedema (see image of device in Figure 1 below).

The device helps move the flow of lymphatic and venous fluid throughout the extremities by stimulating muscles within the affected extremity. This action mimics natural muscle contractions, improves circulation, and moves excess fluid back to the circulatory system so edema can be eliminated from the body.

System components include (a) a mains-powered, portable pneumatic pump with a pressure-control knob and on/off switch (the device contains no control panel or microprocessor circuit); (b) connecting air hoses; and (c) compression garments attached

to patient limbs. In addition, garment inserts allow increase in circumference of arm and leg garments.

The pump intermittently releases compressed air through the tubing into inflating and deflating bladders within cuffs that are wrapped separately around the patient's upper and lower limbs (full arm, full leg, and half leg).

**EzLymph** and **EzLymph M** is intended for home use under the care of personnel authorized and trained to treat lymphedema. The device is intended for patients at risk for the medical condition. The system is portable.

- 8. <u>Mechanism of Action</u>... Intermittent pneumatic compression of air inflates and deflates cuffs attached to affected extremities.
- 9. <u>Indications For Use</u>... Intended to treat lymphedema.

The device is intended for prescription use only.



### 10. Comparison To Predicate & Reference Devices

The subject and predicate devices share the same:

- Intended use To apply intermittent pneumatic compression to arms and legs to relieve the discomfort of lymphedema.
- Indications for use To treat lymphedema (the predicate also claims other indications, as noted in Table 5).
- System design Portable pump, air hoses, compression garments.
- Number of models Two.
- Garment styles Arm, leg.
- Compression methods Uniform, sequential.
- Compression cycle lengths 180 seconds.
- Air chambers Single chamber, multiple chamber.
- Multiple garments Both devices allow treatment with 2 garments.
- Mode of operation Continuous.
- Energy sources Mains power.
- Materials ABS plastic (pump case) and biocompatible fabric (garments).
- Reusability Reusable pump and air tubing; garments are single-patient use.

Minor differences between the subject and predicate devices include:

- <u>Number of compression chambers</u> While both offer single- and multiple-chamber models, for the latter the subject provides 4 chambers compared to the predicate's 3 chambers.
- <u>Compression cycle sequence</u> Both offer 180-second cycles except that the predicate increases cycle length to 120 seconds for cycles that include calf or thigh; since application is continuous over long time periods (days and weeks, not hours or minutes), this difference is immaterial.

The reference device demonstrates substantial equivalence for one physical characteristic, pressure range, for EzLymph.

**Table 5 - Comparison Table** 

Characteristics	Subject Device	Predicate Device <sup>1</sup>	SE Comparison
Device Name	EzLymph, EzLymph M	Hydroven 3 Pump, Hydroven FPR Pump, Hydroven Garments	NA
Manufacturer	Ezcare Medical Corp (Taiwan)	ArjoHuntleigh AB (Sweden)	NA
Estab Registration #	3003801933	3007420694	NA
510k Number	Applied For	K910188	NA
Device Photo (Pump & Air Hoses)	W Etlymph		SEboth portable pumps
Device Photo (Calf/Thigh Garment)			SEsame basic design
Class	II	II	SE
Regulation #	870.5800	870.5800	SE
Product Code	JOW	JOW	SE
Common Description	Lymphedema Pump	Lymphedema Pump	SE
Medical Specialty	Cardiovascular	Cardiovascular	SE
Submission Type	510(k)	510(k)	SE

<sup>&</sup>lt;sup>1</sup> Comparison data for the reference device, Flexitouch (K170216), is shown in "Pressure Range" characteristic on Page 5.0-5.

Intended Use	To apply intermittent pneumatic compression to arms and legs to relieve the discomfort of lymphedema.	To apply intermittent pneumatic compression to arms and legs to treat conditions listed in IFU.	SEsubject intended use is subset of predicate's
Indication For Use	EzLymph & EzLymph M are intended to treat lymphedema.	Intermittent Pneumatic Compression (IPC) is effective in treatment of following clinical conditions, when combined with an individualized monitoring program: Edema (dependent & traumatic), Lymphedema, (primary and secondary), Chronic venous insufficiency, Post phlebotic syndrome, and Acute & chronic wounds including venous leg ulcers & post-surgical wounds. IPC may also be beneficial in management of: Fixed flexion deformity, Arthritic conditions, Lower limb pain due to trauma or surgery, and Lipedema. Selection should be based upon a holistic assessment of patients' individual care needs.	SEsubject intended use (and IFU) is subset of predicate's
Target Population	Sufferers of lymphedema	Sufferers of lymphedema or other clinical conditions listed in IFU	SEsubject intended use is subset of predicate's
Anatomical Site	Arm/Leg	Arm/Leg	SE
Where Used	Home	Home	SE
Rx/OTC/Both	Rx Only	Rx Only	SE
Physical CharacteristicsOverall			
System Description	Portable pump, connecting air hoses, & compressible limb sleeves	Portable pump, connecting air hoses, & compressible limb sleeves	SE
Working Principle	Pneumatic pump supplies compressed air to inflate compression garments attached to patient limbs	Pneumatic pump supplies compressed air to inflate compression garments attached to patient limbs	SE

### **Physical Characteristics--Compression Garment**

Garment Styles	Full Arm, Half Leg, Full Leg	Full Arm, Half Leg, Full Leg	SE
Garment Sizes	EzLymphArm (S,M), Leg (Half,S,M,L); EzLymph MArm (S,M), Leg (Half,S,M,L)	Hydroven 3Single-Chamber Arm (4 lengths), Leg (6 lengths); Triple-Chamber Arm (2 lengths), Leg (6 lengths); Hydroven FPR (all triple-chamber)Arm (2 lengths), Leg (6 lengths).	SEboth offer multiple arm and leg sizes
Garment Inserts	Allow increase in circumference of arm and leg garments.	Allow increase in circumference of arm and leg garments.	SE
Number of Air Chambers (Bladders)	EzLymph1 (arm, leg) and 4 connected bags (arm, leg); EzLymph M4 independent bags (arm, leg)	Hydroven 31 (arm, leg) & 3 connectd bags (arm,leg); Hydroven FPR3 independent bags (arm, leg).	SEminor difference in number of chambers
Compression Uniform	EzLymph (1 & 4-chamber garments)Inflate 90 sec, then deflate 90 sec. Cycle time 180 sec.	Hydroven 3 (1-chamber garments)Inflate 90 sec, then deflate 90 sec. Cycle time 180 sec.	SE
Compression Sequential	EzLymph M (4-chamber) Inflate sequentially from distal (120, 90, 60, & 30 sec respectively), with 10% pressure decrease with each subsequent chamber moving up garment. Then deflate from proximal (60 sec). Cycle time 180 sec.	Hydroven 3 & FPR (3-chamber)Inflate sequentially from distal (114, 76, & 38 sec). Then deflate from proximal (66 sec). Cycle time 180 sec.	SEminor difference in number of chambers
Multiple Garments	2 garments can be used by alternating for every 90 sec. Cycle time is 180 sec (EzLymph only).	2 garments can be used by alternating for every 90 sec. Cycle time is 180 sec (Hydroven 3 only).	SE
Mode of Operation	Continuous	Continuous	SE
Pressure Range	EzLymph: 30-75 mmHg +/- 10% EzLymph M: 30-90 mmHg +/- 10%	Predicate: 30-100 mmHg +/- 5% Reference: 30-75 mmHg	EzLymph: SEminor difference w/reference EzLymph M: SEminor difference w/predicate

### **Physical Characteristics--Pump**

Dimensions (mm)	280L x 140W x 70H	270L x 150W x 105H (Hydroven 3) or 130H (FPR)	SEminor difference
Weight	1.7 kg (3.75lb)	2.4 kg (5.3 lb)	SEminor difference
Energy Source (Mains)	AC 100V-230V (60/50 Hz)	AC 120V (60 Hz)	SEminor difference
Fuse Rating	1A 250V/T1A 250V	F500 mAH 250V	SEminor difference

Ingress Protection	IP21	IPX0	SEminor difference
<b>Control Panel</b>	Mechanical	Not provided	SE
Operating Temp	5C to 40C	10C to 40C	SEminor difference
Storage/Transport	-20C to 70C	-20C to 50C	SEminor difference
Relative Humidity	<93% RH non-condensing	30%-75% (non-condensng)	SEminor difference
Garment Material (Patient Contact)	Nylon fabric with TPU coating	Not provided	SEsubject passed biocompatibility testing
Case Material	ABS plastic	ABS plastic	SE

### **Components & Accessories**

Components	Pump, air hoses, garments	Pump, air hoses, garments	SE
Accessories	User manual	User manual	SE

### **Non-Clinical Testing**

**EzLymph** and **EzLymph M** passed the following non-clinical tests, all of which were performed to current FDA-recognized standards:

- Electrical Safety... IEC 60601-1:2005, Mod
- EMC... IEC 60601-1-2:2014
- Usability Engineering... IEC 62366-1:2015
- Risk Management... ISO 14971:2007
- Home Healthcare... IEC 60601-1-11:2015

The device passed pump functionality testing and garments pressure cyclic testing.

#### Cybersecurity

**EzLymph** and **EzLymph M** is in compliance with FDA's guidance, "Management of Cybersecurity in Medical Devices" (2014). The device is not capable of connecting (wirelessly or hard-wired) to another device, to the Internet or other network, or to portable media (e.g., USB or CD).

#### **Substantial Equivalence**

**EzLymph** and **EzLymph M** successfully followed the pathway to Substantial Equivalence in the FDA guidance document, "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications" (2014). The steps are summarized below:

- The predicate device is legally marketed and was found substantially equivalent through 510(k) premarket submission.
- The subject and predicate devices have the same intended use.
- Technological differences between the subject and predicate were evaluated; none of the differences raised different issues of safety and effectiveness.
- The following methods for evaluation of the effects of different characteristics on safety and effectiveness were deemed acceptable—testing for electrical safety,

EMC, usability engineering, home healthcare, and mechanical performance; and risk management assessment. Evaluation methods were conducted to FDA-recognized standards where applicable.

 Data from these tests demonstrated equivalence and support the indications for use.

In summary, all necessary testing has been performed and the results support the conclusion that **EzLymph** and **EzLymph M** is substantially equivalent to the legally marketed predicate, Hydroven, based on both (a) comparison of intended use, materials, technology, and design and (b) testing to FDA-recognized standards, and the device thus does not raise any concerns of safety or effectiveness.

Based on the information contained within this submission, the applicant concludes that **EzLymph** and **EzLymph M** is substantially equivalent to the identified predicate device and warrants clearance for marketing activities.